Abstract
Cardiovascular and kidney diseases are major public health concerns, imposing significant social, economic, and healthcare burdens. These conditions are closely linked, each increasing the risk of the other. Rather than affecting a single organ, they involve complex interactions among multiple organs. This interplay significantly influences disease progression. Despite medical advancements, these diseases remain associated with higher mortality, reduced quality of life, and societal limitations. Personalized medicine offers hope for better patient care through big data and omics approaches combined with bioinformatics and artificial intelligence. These tools provide a holistic understanding of disease mechanisms, including multi-organ interactions, and can detect diseases more precisely, even before symptoms arise. Big data and omics approaches also address disease complexity and variability, supporting personalized care.
Chairs
- Joachim Jankowski
- Griet Glorieux
The programme
Time | Presentation |
|---|---|
5 min | Introduction to EU-Cost PerMedikGriet Glorieux and Joachim Jankowski |
25 min | Keynote talkOmic Studies in CKD: Diagnostic Opportunities and Therapeutic PotentialMerita Rroji, University of Tirana, Albania |
15 min | Computational drug repositioning in cardiorenal disease: opportunities, challenges, and approachesPaul Perco, Medical University of Innsbruck, Austria, Delta4 GmbH, Vienna, Austria |
15 min | (Prote)omics for superior management of kidney and cardiovascular disease - A thought-provoking impulse from NephrologyJoachim Beige, KfH-Nierenzentrum und Klinikum St. Georg, Nephrologie, Leipzig, Germany |
15 min | The need for AI modelling in CKD using big dataMarta Lopes, NOVA School of Science and Technology, NOVA University of Lisbon, Portugal |
15 min | Calprotectin in vascular calcification and cardiovascular complicationsJulie Klein, Metabolic and Cardiovascular Research Institute, Toulouse, France |
Closing wordsGriet Glorieux and Joachim Jankowski |